Percutaneous ventricular assist devices (pVADs) are used to provide short term circulatory support to patients with poor ventricular function. Use of pVADs as an alternative support option to intra-aortic balloon pumps for high-risk patients undergoing percutaneous coronary intervention (PCI) has increased in recent years. The U.S. market for intra-aortic balloon pump disposable devices comprises conventional and fiber-optic balloon catheters. In 2015, SynCardia was the sole competitor in the U.S. market for artificial heart replacement devices. As of August 2015, the company’s Total Artificial Heart™ was only approved for commercial use as a temporary device. However, the U.S. market for artificial heart replacement devices may soon grow to include permanent artificial heart replacement devices.